Journal
JOURNAL OF CLINICAL VIROLOGY
Volume 66, Issue -, Pages 27-32Publisher
ELSEVIER
DOI: 10.1016/j.jcv.2015.02.018
Keywords
Respiratory syncytial virus; Surveillance; HRSV; Palivizumab; Genotypes; Molecular; Epidemiology
Categories
Funding
- Plan Nacional de I + D + i
- Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio Espanol de Economia y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD12/0015]
- Fondo de Investigacion Sanitaria, Ministerio Espanol de Economia y Competitividad [FIS PI 14/01838]
- European Regional Development Fund (ERDF)
Ask authors/readers for more resources
Background: Human respiratory syncytial virus (HRSV) is the main cause of lower respiratory tract infections among infants and young children. Objectives: The molecular epidemiology and characterization of HRSV strains detected at a Spanish tertiary hospital during the 2013-2014 season is reported. Study design: Phylogenetic analysis and molecular characterization of HRSV laboratory-confirmed respiratory samples were performed, based on coding sequences of G and F proteins. Results: HRSV infection was laboratory-confirmed in respiratory samples from 320 patients of which 223 (70%) were less than 2 years of age and none undergoing Palivizumab treatment. HRSV was detected at varying levels throughout the season with a maximum rate in the week 52/2013, right before the beginning of the influenza epidemic. Whilst both HRSV groups were found co-circulating, HRSV-B group clearly predominated. The phylogenetic analyses from 139 HVR-2 sequences revealed that most characterized strains belonged to ON1 and BA9 genotypes. Three different phylogenetic subgroups could be distinguished within these genotypes. In addition, three strains (out of the 52 randomly selected) were carrying amino acid substitutions in the epitope A of the F protein, one of them previously related to Palivizumab resistance. Conclusions: The results of the present study highlight the importance of a continuous HRSV surveillance to monitor not only the introduction of new genotypes on circulation but also the emergence of viral variants with new genetic characteristics that can affect the antigenicity features and the susceptibility to the only current prophylaxis treatment and also for the future development of HRSV vaccines. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available